Literature DB >> 27929134

Contrast-enhanced transrectal ultrasound for prediction of prostate cancer aggressiveness: The role of normal peripheral zone time-intensity curves.

Hui Huang1, Zheng-Qiu Zhu1, Zheng-Guo Zhou1, Ling-Shan Chen2, Ming Zhao3, Yang Zhang4, Hong-Bo Li1, Li-Ping Yin1,4.   

Abstract

To assess the role of time-intensity curves (TICs) of the normal peripheral zone (PZ) in the identification of biopsy-proven prostate nodules using contrast-enhanced transrectal ultrasound (CETRUS). This study included 132 patients with 134 prostate PZ nodules. Arrival time (AT), peak intensity (PI), mean transit time (MTT), area under the curve (AUC), time from peak to one half (TPH), wash in slope (WIS) and time to peak (TTP) were analyzed using multivariate linear logistic regression and receiver operating characteristic (ROC) curves to assess whether combining nodule TICs with normal PZ TICs improved the prediction of prostate cancer (PCa) aggressiveness. The PI, AUC (p < 0.001 for both), MTT and TPH (p = 0.011 and 0.040 respectively) values of the malignant nodules were significantly higher than those of the benign nodules. Incorporating the PI and AUC values (both, p < 0.001) of the normal PZ TIC, but not the MTT and TPH values (p = 0.076 and 0.159 respectively), significantly improved the AUC for prediction of malignancy (PI: 0.784-0.923; AUC: 0.758-0.891) and assessment of cancer aggressiveness (p < 0.001). Thus, all these findings indicate that incorporating normal PZ TICs with nodule TICs in CETRUS readings can improve the diagnostic accuracy for PCa and cancer aggressiveness assessment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27929134      PMCID: PMC5144131          DOI: 10.1038/srep38643

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Prostate cancer (PCa) is the second most common malignant tumour that affects the male population1. Timely diagnosis of PCa can ensure efficient management of the disease and improve active surveillance in patients with and without clinically significant cancers2. Consequently, the precise evaluation of prostate nodules is vital. Contrast-enhanced transrectal ultrasound (CETRUS) has been used widely to enhance the visualization of perfusion changes related to PCa, and it is regarded as a promising tool for evaluating malignant prostate nodules3. In clinical practice, PCa is confirmed or excluded by transrectal ultrasound-targeted biopsy, based on the results of digital rectal examination or serum prostate-specific antigen (PSA) levels4, and perfusion analysis by CETRUS5. However, recent findings have demonstrated that CETRUS is of limited value for evaluating the aggressiveness of PCa, owing to its varying sensitivity and specificity56. PCa generally exhibits altered angiogenic microvascular structures and blood flow patterns, which characterize the aggressiveness of this cancer and form the basis of diagnosis based on CETRUS78. However, the flow pattern signals of this malignancy are often subtle and disappear within seconds; the efficiency of this method is therefore highly user dependent. Therefore, quantitative techniques that extract perfusion parameters to distinguish between malignant and benign tissue are being developed from CETRUS recordings: one of these techniques is the creation of time-intensity curves (TICs). TICs include many crucial parameters, such as arrival time (AT)9, mean transit time (MTT) and rise time10, time to peak (TTP) and peak intensity (PI)9, among others. These quantitative indices are reported to have high diagnostic accuracy and lesser user dependency. However, the discriminative power of these indices depends in part on the “background” variability of tissue heterogeneity, which when eliminated improves the diagnostic accuracy of magnetic resonance imaging (MRI) for PCa detection11. However, to date, although CETRUS is a commonly used modality for the diagnosis of malignant prostate nodules, TICs of the normal peripheral zone (PZ) are still rarely taken into account. Therefore, the aim of this study was to evaluate the role of normal PZ TICs for the detection of PCa and assessment of cancer aggressiveness, and to determine whether the diagnostic accuracy improves significantly, compared to the biopsy findings, when normal PZ quantitative parameters are incorporated.

Material and Methods

This study was approved by the ethics committee of the Jiangsu Province Hospital of Traditional Chinese Medicine, and the methods were carried out in accordance with the relevant guidelines. Written informed consent was obtained from all patients.

Patients

Between May 2014 and March 2016, 132 patients with abnormal digital rectal examination findings and/or elevated serum PSA levels (≥4 ng/ml and ≤10 ng/ml) who had not previously undergone biopsy were enrolled in this study. All the patients underwent CETRUS, which was performed by an experienced operator, and all the CETRUS data were independently reviewed frame by frame on the scanner by two other experienced investigators who were blinded to the greyscale imaging and pathological results. Then, a systematic twelve-core transrectal ultrasound-guided prostate biopsy and two-core targeted biopsy were performed based on the abnormal sonography findings by an experienced operator from the Department of Urology, who was assisted by the CETRUS operator mentioned earlier.

CETRUS procedure

Each patient was evaluated using ultrasonography at the baseline and again during intravenous infusion of sulphur hexafluoride microbubbles (SonoVue; Bracco, Milan, Italy) (Fig. 1a,b). An IU-22 ultrasound system (Philips, Amsterdam, The Netherlands) with a transrectal end-fire transducer (c8-4v) was used. Normal greyscale imaging was performed with a probe frequency of 4 to 8 MHz and a dynamic range of 55 dB. For colour Doppler ultrasonography, the probe frequency was 6 MHz, and the colour Doppler gain was adjusted to maximize signal but eliminate colour noise from the tissue of the prostate. The colour Doppler window was set to include the entire gland. During the contrast-enhanced ultrasound examinations, a fast bolus injection of 2.4 ml SonoVue was administered intravenously; this was followed by administration of 5 ml of normal saline flush. The scanner was set in the contrast pulse-sequencing mode with a probe frequency of 8 MHz. The acoustic power was set at a mechanical index of 0.13, and the dynamic range was fixed at 55 dB. The transverse plane of the sonographic abnormality was chosen for contrast imaging. In patients with no suspicious baseline ultrasonography results, the most hypervascular plane on colour Doppler images was chosen. The entire examination was saved in a Digital Imaging and Communications in Medicine format and transmitted to a workstation for further analysis (Fig. 1c).
Figure 1

The region of interest (ROI) settings, time-intensity curve (TIC) analysis and oncological outcomes.

Transverse (a) greyscale and (b) contrast-enhanced transrectal ultrasound mapping of the prostate in a 67-year-old patient. The red box indicates the ROI placed in the nodule lesion, and the yellow box indicates the corresponding ROI placed in the normal peripheral zone (PZ). (c) The red and yellow lines in the TICs represent the perfusion characteristics of the ROIs of the nodules and the normal PZ, respectively. (d) The oncological outcomes following biopsy show an adenocarcinoma.

Image analysis

All CETRUS data were analyzed on the workstation using the QLAB quantification software (Philips) by a sonographer who was blinded to all the clinical and pathological information (Fig. 1c). Considering that the enhancement characteristics of the PZ lesions were completely different from those of the transition zone lesions, which may reflect the hypervascularity of the normal inner gland and coexisting benign prostate hyperplasia, only the PZ was evaluated in this study. Therefore, duplicated regions of interest (ROIs) were drawn in the targeted biopsy and normal PZ site on contrast ultrasonographic images, and the diameters were set to approximately 5 mm. The TICs were reconstructed for each ROI, and then the relative quantitative parameters, which depicted the features of prostate tissue infusion in the ROI that were observed after time zero, were measured by three well-trained observers. The average of all the measurements was calculated.

Analysis of oncological outcomes

Biopsy specimens were labelled according to the location from which they were obtained and fixed with a 10% formaldehyde solution in separate test tubes. The pathological findings were assessed by an experienced pathologist as benign prostatic hyperplasia, acute or chronic prostatitis, or prostatic intraepithelial neoplasia or carcinoma (Fig. 1d). The grade of the tumour was also evaluated and assigned a standard Gleason score (Table 1).
Table 1

Clinical and pathologic characteristics of the patients.

CharacteristicValue
No. of patients132
No. of PZ nodules134
Clinical characteristics*Benign lesions** (n = 80)Malignant lesions (n = 54)p value
Age (y)65.9 ± 9.067.1 ± 10.80.475
PSA (ng/ml)5.2 ± 3.05.9 ± 3.10.211
Prostate volume (cm3)50.1 ± 26.543.3 ± 13.10.206
Gleason scoreNo. of lesions, n (%)
54 (7.4)
619 (35.2)
721 (38.9)
87 (13.0)
93 (5.5)

PZ: peripheral zone, PSA: prostate-specific antigen.

*Data are shown as the mean ± standard deviation.

**Benign: 76, benign prostatic hyperplasia; 4, chronic prostatitis.

Statistical analysis

Student’s t-test was used to analyze differences in the quantitative parameters of TICs between benign and malignant lesions (Table 2). Multivariate logistic regression was used to test our first hypothesis: joint analysis of the nodule TICs (e.g. PI in this section) and the normal PZ PI results in better prediction of PCa. We can express the regression model for the probability of malignancy as follows:
Table 2

Quantitative parameters of the nodule and normal peripheral zone time-intensity curves.

ParametersNodules (n = 130)
Normal peripheral zone (n = 130)
Benign lesions (n = 76)Malignant lesions (n = 54)p valueBenign lesions (n = 76)Malignant lesions (n = 54)p value
AT (s)22.0 ± 6.022.7 ± 4.80.51221.7 ± 6.421.8 ± 5.70.913
PI (dB)12.6 ± 4.417.2 ± 3.9<0.00113.4 ± 4.811.8 ± 3.60.052
MTT (s)32.3 ± 9.837.0 ± 10.40.01130.4 ± 9.533.9 ± 9.20.036
AUC (dB/s)685.1 ± 334.11055.3 ± 404.4<0.001705.5 ± 362.8699.1 ± 273.30.912
TPH (s)46.5 ± 15.752.3 ± 15.80.04044.3 ± 15.048.4 ± 14.20.119
WIS (dB/s)1.4 ± 0.61.5 ± 0.60.6121.5 ± 0.81.1 ± 0.60.001
TTP (s)32.4 ± 8.230.5 ± 5.90.14931.7 ± 9.133.7 ± 7.30.198

AT: arrival time; PI: peak intensity; MTT: mean transit time; AUC: area under the curve; TPH: time from peak to one half; WIS: wash in slope; TTP: time to peak. Values are shown as the mean ± standard deviation.

Eqs (1) and (2) are the regression equations calculated for the model using nodule PI only and the nodule and normal PZ PI together. The subscripts D and N represent the nodule and normal PZ, respectively. B and C represent the regression coefficient and regression constant, respectively, that correspond to these variables. Subsequently, the z values are calculated from Eqs (1) and (2), and the continuous variables are converted from the two categorical dependent variables (benign or malignant) to calculate the probability of malignancy. However, the range of values from positive to negative is large, which makes comparison difficult. Therefore, Eq. (3) represents Poisson’s conversion from z to the probability of malignancy, p, which ranged from 0 to 1. The PID and PIN values and the significance of these variables in the multivariate logistic regression model are presented in Table 3.
Table 3

Multivariate logistic regression of the quantitative parameters of TICs based on Eqs (1 and 2).

 
BDBNC
ParametersValuep valueValuep valueValuep value
ATATD only0.0210.509−0.8160.271
 ATD + ATN0.0230.508−0.0040.903−0.7640.369
PIPID only0.275<0.001− 4.5020.007
 PID + PIN0.716<0.001−0.586<0.001− 3.4900.001
MTTMTTD only0.0460.014−1.9470.004
 MTTD + MTTN0.0370.0760.0230.285−2.3740.003
AUCAUCD only0.003<0.001−2.715<0.001
 AUCD + AUCN0.009<0.001−0.008<0.001−1.9850.001
TPHTPHD only0.0240.041−1.5410.013
 TPHD + TPHN0.0210.1590.0050.750−1.6290.017
WISWISD only0.1560.253−0.5660.239
 WISD + WISN0.4790.163−1.0430.0010.2950.595
TTPTTPD only−0.0360.1510.8020.323
 TTPD + TTPN−0.0560.0500.0450.061−0.0610.948

AT: arrival time; PI: peak intensity; MTT: mean transit time; AUC: area under the curve; TPH: time from peak to one half; WIS: wash in slope; TTP: time to peak.

D = nodule peripheral zone tissue, N = normal peripheral zone tissue, B = regression coefficient, C = regression constant.

Our second hypothesis was that the improved prediction of PCa results in a significant improvement in diagnostic accuracy in differentiating between benign and malignant nodules. Utilizing the receiver operating characteristic (ROC) curves constructed from malignant probability (p) values, we created a standalone PID regression model based on Eq. (1) and a joint regression model incorporating PIN from Eq. (2) to compare diagnostic accuracy. The differences between areas under the ROC curve were calculated using statistical methods described by DeLong et al.12 and Hanley et al.13 Furthermore, a visual assessment of the correlation between nodule PI and normal PZ PI was provided by plotting the benign and malignant nodules with respect to their PI and the corresponding normal PZ PI. Our third hypothesis was that including normal PZ TICs significantly improves the differentiation of cancer aggressiveness between low-grade and high-grade tumours. Generally, tumours with a Gleason score of 7, 8 or 9 are defined as high-grade tumours, whereas tumours with a Gleason score of 5 or 6 are defined as low-grade tumours1114. Using box plot analysis, we established a standalone PID regression model and incorporated the PIN model into it to compare the probability of malignancy (p) and test for significant differences. All statistical analyses were carried out using SPSS Statistics, version 18 (IBM, Chicago, USA). P < 0.05 was considered to indicate statistical significance.

Results

Clinical and pathological characteristics

The clinical and pathological characteristics of 132 patients with 134 nodules are listed in Table 1. The results of pathologic examination of the target biopsy samples revealed that there were 54 malignant and 80 benign lesions. Of the 80 benign lesions, 4 nodules were excluded from further analysis as they were identified as chronic prostatitis nodules (n = 4). There was no significant difference between the benign and malignant groups with regard to age, PSA and prostate volume (p = 0.475, 0.211 and 0.206, respectively). Among the 54 malignant lesions, four lesions had a Gleason score of 5 (7.4%, 4 of 54); 19 lesions had a Gleason score of 6 (35.2%, 19 of 54); 21 lesions, 7 (38.9%, 21 of 54); seven lesions, 8 (13.0%, 7 of 54); and three lesions, 9 (5.5%, 3 of 54).

Analysis of the quantitative parameters of TICs

The results of analysis of the quantitative parameters of prostate lesions and normal PZ TICs are shown in Table 2. Total TIC analysis showed that PI (p < 0.001), MTT (p = 0.011), area under the curve (AUC) (p < 0.001) and time from peak to one half (TPH) (p = 0.040) were significantly higher in the malignant nodules than in the benign nodules, but AT, wash in slope (WIS) and TTP were not significantly higher (p = 0.512, 0.612, and 0.149, respectively; Table 2). Moreover, the TIC parameters of normal PZ tissue were not significantly different between benign and malignant lesions, except for MTT and WIS (p = 0.036 and 0.001, respectively; Table 2). Multivariate logistic regression analysis showed that nodule PI (p < 0.001), MTT (p = 0.014), AUC (p < 0.001) and TPH (p = 0.041) were significant factors with regard to the prediction of PCa, but AT, WIS and TTP were not significant factors (p = 0.509, 0.253 and 0.151, respectively; Table 3).

The effect of incorporating normal PZ PI, AUC, MTT or TPH in the prediction of PCa

Normal PZ TICs, which reflect the “background” characteristics of prostate tissue, are correlated with the TICs of PZ in prostate nodules. By using logistic regression and Eqs (1) and (2), a regression model using only nodule TIC parameters can be expressed as Eqs (4) and (5), shown below: The model incorporating PID and PIN or AUCD and AUCN can be expressed as Eqs (6) and (7) respectively: In both regression models, a dramatic change was introduced by the addition of nodule PI (p < 0.001, PID alone; p < 0.001, PID including PIN, Table 3), nodule AUC (p < 0.001, AUCD alone; p < 0.001, AUCD including AUCN, Table 3), normal PZ PI (p < 0.001; Table 3) and AUC (p < 0.001; Table 3); this significantly improved the prediction of malignancy. Table 4 and Fig. 2a show the ROC curves for the probability value p based on the regression models of Eqs (4) and (6): the area under the ROC curve increased by 17.7%, from 0.784 (95% CI, 0.704–0.865) to 0.923 (95% CI, 0.876–0.969) (p < 0.001, according to both the DeLong and Hanley methods). Table 4 and Fig. 2b show that the area under the ROC curve based on the regression models of Eqs (5) and (7) increased by 17.5%, from 0.758 (95% CI, 0.673–0.843) to 0.891 (95% CI, 0.832–0.951) (p < 0.001, according to both the DeLong and Hanley methods).
Table 4

Diagnostic performance of the nodule parameters only and both the nodule parameters and normal peripheral zone PI or AUC.

ParametersSensitivity (%)Specificity (%)PPV (%)NPV (%)AUC (%)
PIPID only66.7 (36/54)73.7 (56/76)64.3 (36/56)75.7 (56/74)78.4 (70.4–86.5)
 PID + PIN79.6 (43/54)90.8 (69/76)86.0 (43/50)86.3 (69/80)92.3 (87.6–96.9)
AUCAUCD only53.7 (29/54)81.6 (62/76)67.4 (29/43)71.3 (62/87)75.8 (67.3–84.3)
 AUCD + AUCN72.2 (39/54)92.1 (70/76)86.7 (39/45)82.4 (70/85)89.1 (83.2–95.1)

PI: peak intensity, AUC: area under the curve, PPV: positive predictive value, NPV: negative predictive value. D = nodule peripheral zone tissue, N = normal peripheral zone tissue.

The AUC values are followed by the 95% CIs in parentheses.

Figure 2

Receiver operating characteristic curve of the regression models based on Eq. (3).

The solid line shows the diagnostic accuracy when the model incorporates (a) the normal peripheral zone (PZ) peak intensity (PI) in addition to the nodule PIs and (b) the normal PZ area under the curve (AUC) in addition to the nodule AUCs. The dotted line shows the diagnostic accuracy of (a) nodule PIs only and (b) nodule AUCs only.

However, incorporating the normal MTT or TPH (p = 0.285, MTTN; p = 0.750, TPHN; Table 3) failed to improve the prediction accuracy of PCa.

Diagnostic accuracy of the regression models

Incorporating PIN dramatically improved tumour diagnostic accuracy (p < 0.001; PID only, p < 0.001), as did the inclusion of AUCN (p < 0.001; AUCD only, p < 0.001). When only PID was incorporated into the regression model, the specificity, sensitivity, positive predictive value (PPV) and negative predictive value (NPV) were 73.7%, 66.7%, 64.3% and 75.7%, respectively; when PIN was also included, these values increased to 90.8% (69 of 76), 79.6% (43 of 54), 86.0% (43 of 50) and 86.3% (69 of 80), respectively. Similarly, when only AUCD was incorporated in the regression model, the specificity, sensitivity, PPV and NPV were 81.6%, 53.7%, 67.4% and 71.3%, respectively; when AUCN was also incorporated, these values increased to 92.1% (70 of 76), 72.2% (39 of 54), 86.7% (39 of 45), and 82.4% (70 of 85), respectively.

Correlation between nodule TICs and normal PZ TICs

In combination with Eq. (3), the regression models established depict the probability of a given nodule being a prostatic malignancy. Based on the models that also incorporate PIN or AUCN (Fig. 3a,b), it seems that a relatively low PID or AUCD might still be indicative of a highly suspicious tumour if the PIN or AUCN is also low. Thus, the diagnostic accuracy of a threshold based on only the PID or AUCD value alone may not be very high (decision line in Fig. 3a,b).
Figure 3

Scatter plots and decision boundary of the (a) model incorporating the nodule peak intensity (PI) and the normal peripheral zone (PZ) PI and (b) the model incorporating the nodule area under the curve (AUC) and the normal PZ AUC. The line represents the decision boundary; the solid dots, the malignant lesions; and the looped dots, the benign lesions.

Assessment of cancer aggressiveness based on the regression models

Based on the probability of malignancy (p) of the regression models, it seems that both the PID only and PID plus PIN models are significant with regard to differentiating between low-grade tumours and benign lesions (p < 0.001 for both, Fig. 4a,b). Moreover, the PID plus PIN model is significant for differentiating between high-grade tumours and benign lesions (p < 0.001, Fig. 4b), but the PID only model is not (p = 0.080, Fig. 4a). Moreover, the inclusion of nodule PI along with normal PZ PI resulted in a significant improvement in the differentiation of high-grade tumours from benign nodules (p < 0.001 for both, Fig. 4a,b).
Figure 4

Box plot analysis of the probability of malignancy (p) based on (a) nodule peak intensity (PI) only and (b) normal peripheral zone (PZ) PI in the benign (n = 76), low-grade (n = 23) and high-grade tumour (n = 31) groups.

Discussion

Several studies have reported that CETRUS has high diagnostic sensitivity and specificity for the prediction of PCa910. However, with regard to TICs, the most accurate quantitative parameters differ greatly from each other910, which means that the diagnostic accuracy of the parameters vary. In this study, we found that the perfusion indices PI, MTT, AUC and TPH are significant factors with regard to the prediction of PCa (Tables 2 and 3). However, when the malignancy risk was assessed based on nodule TICs only, there was no evidence to show that any of these factors is significantly better than the others. Moreover, certain other indices that were found to be significant in previous studies on PCa9 and liver1516 and breast17 cancer did not appear significant in our findings, for example, AT (Tables 2 and 3). It is possible that if the inter-patient variation is eliminated or heterogeneity is adjusted for, the diagnostic accuracy of these factors for PCa may improve. In CETRUS recordings, the entire prostate is represented by groups of data points; moreover, current studies often focus on the PZ hyperperfusion region rather than the whole prostate and do not conduct tissue analysis of other normal tissue181920. Here, we show that incorporating normal tissue TICs could significantly improve the diagnostic accuracy of nodule TICs for PCa detection (Fig. 2a,b). This is consistent with the finding that including background information enhances the discriminative ability of MRI for PCa11. Interestingly, the other TIC parameters, such as MTT and TPH, improved the prediction of PCa by themselves, but incorporation of the corresponding normal PZ parameters did not improve PCa prediction (Table 3). This finding indicates that “background” prostate PZ perfusion characteristics affect the “Y-axis” intensity parameters of TICs, such as PI or AUC, but they do not affect the “X-axis” time parameters such as MTT and TPH. Our results also demonstrate that low nodule TIC values are suggestive of a potential malignancy in the presence of low normal PZ TIC values. Thus, it is not feasible to set any standard diagnostic threshold values for nodules or normal parameters (Fig. 3a,b). The incorporation of PID plus PIN or AUCD plus AUCN significantly affected the differentiation ability of TICs. However, it not clear whether the TIC values are useful for the precise assessment of cancer aggressiveness, which is commonly estimated by the Gleason score and largely influences PCa management2122. Moreover, the contrast-enhanced CETRUS findings for the PCa lesions showed various patterns according to tumour vascularity2324 and aggressiveness2526; this is indicative of the heterogeneity of this cancer. In our study, incorporating TICs enabled the differentiation of low-grade tumours (n = 23) from high-grade ones (n = 31) (Fig. 4b). This finding indicates that normal PZ TICs play a novel role in the assessment of cancer aggressiveness. This study had several limitations. Firstly, the use of TICs to assess transition zone tumours has not been investigated. Given that the majority of PCa’s arise in the PZ, this is a major limitation of this study. Secondly, ultrasound-guided prostate biopsy has inevitable false positive and false negative outcomes, which may have affected the final results of our study. Thirdly, the validity of the cancer aggressiveness assessment should be further tested in a large, prospective and multi-cohort study. In conclusion, our findings demonstrate that incorporating the perfusion characteristics of normal PZ tissue may enable the identification of malignancies based on the quantitative TIC parameters of CETRUS. Thus, this is a novel approach that uses inter-patient differences for PCa prediction and assessment of cancer aggressiveness.

Additional Information

How to cite this article: Huang, H. et al. Contrast-enhanced transrectal ultrasound for prediction of prostate cancer aggressiveness: The role of normal peripheral zone time-intensity curves. Sci. Rep. 6, 38643; doi: 10.1038/srep38643 (2016). Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
  26 in total

Review 1.  Imaging modalities in focal therapy: patient selection, treatment guidance, and follow-up.

Authors:  Berrend G Muller; Willemien van den Bos; Peter A Pinto; Jean J de la Rosette
Journal:  Curr Opin Urol       Date:  2014-05       Impact factor: 2.309

2.  Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis.

Authors:  Moon Young Kim; Ki Tae Suk; Soon Koo Baik; Hyoun A Kim; Young Ju Kim; Seung Hwan Cha; Hwa Ryun Kwak; Mee Yon Cho; Hong Jun Park; Hyo Keun Jeon; So Yeon Park; Bo Ra Kim; Jin Heon Hong; Ki Won Jo; Jae Woo Kim; Hyun Soo Kim; Sang Ok Kwon; Sei Jin Chang; Gwang Ho Baik; Dong Joon Kim
Journal:  Hepatology       Date:  2012-07-12       Impact factor: 17.425

3.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

4.  First results of endocavity evaluation of the microvascularization of malignant prostate tumors using contrast enhanced ultrasound (CEUS) including perfusion analysis: first results.

Authors:  E M Jung; P Wiggermann; C Greis; F Eder; J Ehrich; W Jung; A G Schreyer; C Stroszczynski; R Ganzer
Journal:  Clin Hemorheol Microcirc       Date:  2012       Impact factor: 2.375

5.  Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.

Authors:  M L Blute; E J Bergstralh; A Iocca; B Scherer; H Zincke
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

Review 6.  Can we deliver randomized trials of focal therapy in prostate cancer?

Authors:  Hashim U Ahmed; Viktor Berge; David Bottomley; William Cross; Rakesh Heer; Richard Kaplan; Tom Leslie; Chris Parker; Clare Relton; Richard Stephens; Matthew R Sydes; Lindsay Turnbull; Jan van der Meulen; Andrew Vickers; Timothy Wilt; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2014-04-22       Impact factor: 66.675

7.  Interpatient variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness.

Authors:  Geert J S Litjens; Thomas Hambrock; Christina Hulsbergen-van de Kaa; Jelle O Barentsz; Henkjan J Huisman
Journal:  Radiology       Date:  2012-08-24       Impact factor: 11.105

8.  The value and limitations of contrast-enhanced transrectal ultrasonography for the detection of prostate cancer.

Authors:  Han-Xue Zhao; Chun-Xia Xia; Hong-Xia Yin; Ning Guo; Qiang Zhu
Journal:  Eur J Radiol       Date:  2013-08-03       Impact factor: 3.528

Review 9.  Angiogenesis in prostate cancer: onset, progression and imaging.

Authors:  Giovanna Russo; Massimo Mischi; Wout Scheepens; Jean J De la Rosette; Hessel Wijkstra
Journal:  BJU Int       Date:  2012-09-07       Impact factor: 5.588

10.  Contrast enhanced ultrasound flash replenishment method for directed prostate biopsies.

Authors:  Robert A Linden; Edouard J Trabulsi; Flemming Forsberg; Paul R Gittens; Leonard G Gomella; Ethan J Halpern
Journal:  J Urol       Date:  2007-10-22       Impact factor: 7.450

View more
  7 in total

1.  Prostate cancer diagnosis and treatment using multiparametric transrectal ultrasonography.

Authors:  Koji Okihara
Journal:  J Med Ultrason (2001)       Date:  2019-10       Impact factor: 1.314

2.  The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer.

Authors:  Xin Zhang; Danyan Liang; Hua Hong
Journal:  Cancer Imaging       Date:  2022-10-18       Impact factor: 5.605

Review 3.  Contrast-Enhanced Transrectal Ultrasound in Focal Therapy for Prostate Cancer.

Authors:  Akbar N Ashrafi; Nima Nassiri; Inderbir S Gill; Mittul Gulati; Daniel Park; Andre L de Castro Abreu
Journal:  Curr Urol Rep       Date:  2018-08-28       Impact factor: 2.862

4.  Effect of iodinated contrast media on renal perfusion: A randomized comparison study in pigs using quantitative contrast-enhanced ultrasound (CEUS).

Authors:  Philipp Lamby; Friedrich Jung; Stefanie Graf; Lotte Schellenberg; Johannes Falter; Natascha Platz-da-Silva; Stephan Schreml; Lukas Prantl; Ralf P Franke; Ernst M Jung
Journal:  Sci Rep       Date:  2017-10-13       Impact factor: 4.379

5.  Association Between Contrast-Enhanced Ultrasound Indicators and Prostate Cancer Biochemical Recurrence After Treatment.

Authors:  Jiang-Jun Mei; Yun-Xin Zhao; Yi Jiang; Jian Wang; Jia-Shun Yu
Journal:  Cancer Manag Res       Date:  2020-06-25       Impact factor: 3.989

6.  Multiparametric transrectal ultrasound for the diagnosis of peripheral zone prostate cancer and clinically significant prostate cancer: novel scoring systems.

Authors:  Tong Chen; Fei Wang; Hanbing Chen; Meng Wang; Peiqing Liu; Songtao Liu; Yibin Zhou; Qi Ma
Journal:  BMC Urol       Date:  2022-04-19       Impact factor: 2.264

7.  Contrast-enhanced transrectal ultrasound can reduce collection of unnecessary biopsies when diagnosing prostate cancer and is predictive of biochemical recurrence following a radical prostatectomy in patients with localized prostate cancer.

Authors:  Hong-Wei Zhao; Jian Li; Jia-Zheng Cao; Juan Lin; Zhu Wang; Jian-Yao Lv; Jin-Huan Wei; Zhen-Hua Chen; Hao-Hua Yao; Yi-Hui Pan; Zhen-Li Gao; Jun-Hang Luo; Wei Chen; Lei Shi; Yong Fang
Journal:  BMC Urol       Date:  2020-07-16       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.